Document Type |
: |
Project |
Document Title |
: |
Mutational analysis of RET proto-oncogene receptors in medulary thyroid carcinoma patients in Jeddah دراسة الطفرات الجينية في الجين الخاص للمستقبل RET في مرضى سرطان الغدة الدرقية في مدينة جدة. |
Subject |
: |
Mutational analysis of RET proto-oncogene receptors in medulary thyroid carcinoma patients in Jeddah |
Document Language |
: |
Arabic |
Abstract |
: |
Thyroid cancer represents approximately 1% of malignancies occurring in the world, accounting for an estimated 33,550 cancer diagnoses and 1,530 cancer deaths per year. Of these cancers, 2% to 3% are medullary thyroid cancer (MTC). Average survival for MTC is lower than that for more common thyroid cancers, e.g., 83% 5-year survival for MTC compared to 90% to 94% 5-year survival for papillary and follicular thyroid cancer. Survival is correlated with stage at diagnosis, and decreased survival in MTC can be accounted for in part by a high proportion of late-stage diagnoses. A Surveillance, Epidemiology, and End Results (SEER) population-based study of medullary thyroid cancer patients found that survival varied by extent of local disease. For example, the 10-year survival rates ranged from 95.6% for disease confined to the thyroid gland to 40% for those with distant metastases.
MTC arises from the parafollicular calcitonin-secreting cells of the thyroid gland. MTC occurs in sporadic and familial forms and may be preceded by C-cell hyperplasia (CCH), though CCH is a relatively common abnormality in middle-aged adults. In a population-based study in Europe, 26% of patients with MTC had the familial form. A French national registry nd a U. S. clinical series both reported a higher proportion of familial cases (43% and 44%, respectively). Familial cases often indicate the presence of multiple endocrine neoplasia type 2, a group of autosomal dominant genetic disorders caused by inherited mutatiuons in the RET proto-oncogene.
In addition to early stage at diagnosis, other factors associated with improved survival in MTC include smaller tumor size, younger age tat diagnosis, familial versus sporadic form, and diagnosis by biochemical screening (i.e., screening for calcitonin elevation) versus symptoms. |
Publishing Year |
: |
1428 AH
2007 AD |
Added Date |
: |
Tuesday, June 29, 2010 |
|
Researchers
ممدوح قاري عبد الله قاري | Gari, Mamdooh Abdullah | Investigator | Doctorate | |
|